Sigma-1R Protects Retinal Ganglion Cells in Optic Nerve Crush Model for Glaucoma.


Journal

Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701

Informations de publication

Date de publication:
02 08 2021
Historique:
entrez: 18 8 2021
pubmed: 19 8 2021
medline: 28 9 2021
Statut: ppublish

Résumé

The purpose of this study was to determine the effects of the Sigma-1R (σ-1r) on retinal ganglion cell (RGC) survival following optic nerve crush (ONC) and the signaling mechanism involved in the σ-1r protection. The overall strategy was to induce injury by ONC and mitigate RGC death by increasing σ-1r expression and/or activate σ-1r activity in σ-1r K/O mice and wild type (WT) mice. AAV2-σ-1r vector was used to increase σ-1r expression and σ-1r agonist used to activate the σ-1r and RGCs were counted. Immunohistochemical and Western blot analysis determined phosphorylated (p)-c-Jun, c-Jun, and Caspase-3. Pattern electroretinography (PERG) determined RGC activity. RGC counts and function were similar in pentazocine-treated WT mice when compared to untreated mice and in WT mice when compared with σ-1r K/O mice. Pentazocine-induced effects and the effects of σ-1r K/O were only observable after ONC. ONC resulted in decreased RGC counts and activity in both WT and σ-1r K/O mice, with σ-1r K/O mice experiencing significant decreases compared with WT mice. The σ-1r transgenic expression resulted in increased RGC counts and activity following ONC. In WT mice, treatment with σ-1r agonist pentazocine resulted in increased RGC counts and increased activity when compared with untreated WT mice. There were time-dependent increases in c-jun, p-c-jun, and caspase-3 expression in ONC mice that were mitigated with pentazocine-treatment. These findings suggest that the apoptotic pathway is involved in RGC losses seen in an ONC model. The σ-1r offers neuroprotection, as activation and/or transgenic expression of σ-1r attenuated the apoptotic pathway and restored RGCs number and function following ONC.

Identifiants

pubmed: 34406331
pii: 2776609
doi: 10.1167/iovs.62.10.17
pmc: PMC8375012
doi:

Substances chimiques

Receptors, sigma 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

17

Références

Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2412-21
pubmed: 10937548
Invest Ophthalmol Vis Sci. 2015 Sep 1;56(10):6144-61
pubmed: 26397462
Neurosci Lett. 2011 Nov 14;505(2):76-81
pubmed: 21996423
EMBO J. 2006 Mar 8;25(5):1058-69
pubmed: 16511568
Br J Ophthalmol. 2007 Oct;91(10):1382-4
pubmed: 17522150
J Biomed Sci. 2017 Sep 16;24(1):74
pubmed: 28917260
J Neurosci Res. 2006 Apr;83(5):907-18
pubmed: 16477618
Neurobiol Dis. 2012 May;46(2):393-401
pubmed: 22353563
Adv Exp Med Biol. 2020;1131:699-718
pubmed: 31646531
Exp Eye Res. 2013 Feb;107:21-31
pubmed: 23183135
Invest Ophthalmol Vis Sci. 2008 Sep;49(9):4154-61
pubmed: 18469181
Exp Eye Res. 2005 May;80(5):663-70
pubmed: 15862173
Trends Cell Biol. 2009 Feb;19(2):81-8
pubmed: 19144519
J Comp Neurol. 2014 Apr 15;522(6):1411-43
pubmed: 24318667
Exp Eye Res. 2014 Nov;128:156-69
pubmed: 25305575
Invest Ophthalmol Vis Sci. 2017 May 1;58(5):2755-2764
pubmed: 28549090
Neurosci Lett. 2019 Oct 15;711:134387
pubmed: 31330223
Mol Neurobiol. 2017 Jan;54(1):72-86
pubmed: 26732591
Free Radic Biol Med. 2015 Sep;86:25-36
pubmed: 25920363
Sci Rep. 2015 Jun 02;5:10689
pubmed: 26033680
PLoS One. 2013 Nov 12;8(11):e79183
pubmed: 24265756
Prog Retin Eye Res. 2018 Nov;67:130-149
pubmed: 30075336
Invest Ophthalmol Vis Sci. 1999 Apr;40(5):1004-8
pubmed: 10102300
Mol Neurodegener. 2016 Apr 21;11:30
pubmed: 27098079
PLoS One. 2017 Sep 12;12(9):e0184421
pubmed: 28898265
Invest Ophthalmol Vis Sci. 2011 Sep 29;52(10):7749-60
pubmed: 21862648
Ophthalmic Epidemiol. 2006 Aug;13(4):283-9
pubmed: 16877288
Cell Mol Neurobiol. 2016 May;36(4):531-40
pubmed: 26119305
Mol Vis. 2011 Apr 26;17:1034-43
pubmed: 21541278
Nature. 2005 Sep 8;437(7056):281-5
pubmed: 16007074
J Neurosci Res. 1993 Feb 1;34(2):250-5
pubmed: 8450568
Invest Ophthalmol Vis Sci. 2010 Feb;51(2):1052-8
pubmed: 19737887
Mol Vis. 2012;18:2860-70
pubmed: 23233788
Neuroreport. 2005 Aug 1;16(11):1223-6
pubmed: 16012353
Cell. 2007 Nov 2;131(3):596-610
pubmed: 17981125
Pharmacol Ther. 2009 Nov;124(2):195-206
pubmed: 19619582
Mol Vis. 2011 Apr 06;17:864-75
pubmed: 21527996

Auteurs

Linya Li (L)

Department of Pharmacology and Neuroscience University of North Texas Health Science Center, Fort Worth, Texas, United States.

Shaoqing He (S)

North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, Texas, United States.

Yang Liu (Y)

Department of Pharmacology and Neuroscience University of North Texas Health Science Center, Fort Worth, Texas, United States.
North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, Texas, United States.

Thomas Yorio (T)

Department of Pharmacology and Neuroscience University of North Texas Health Science Center, Fort Worth, Texas, United States.
North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, Texas, United States.

Dorette Z Ellis (DZ)

Department of Pharmaceutical Sciences, University of North Texas Systems College of Pharmacy, University of North Texas Health Science Center, Fort Worth, Texas, United States.
North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, Texas, United States.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH